HONG KONG – Astellas Pharma Inc. proceeded with an exclusive option to acquire Potenza Therapeutics Inc. under a warrant purchase agreement. Tokyo-based Astellas paid Potenza an upfront fee of $164.6 million to acquire the Cambridge, Mass.-based biopharma.